Status:
RECRUITING
Protective Effect of CoQ10 Against Negative Inflammatory Response and Organ Dysfunction in Cardiovascular Surgery (PANDA V)
Lead Sponsor:
Nanjing Medical University
Collaborating Sponsors:
The First Affiliated Hospital with Nanjing Medical University
Beijing Anzhen Hospital
Conditions:
Cardiovascular Disease
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Cardiovascular diseases are the leading causes of death and prescription drug use. Research on certain dietary supplements looks promising as a way to help reduce risk factors. Previous studies showed...
Eligibility Criteria
Inclusion
- Adult men and women
- Who receive cardiovascular surgery
- Agree to participate in the surgery and sign the informed consent form
Exclusion
- Pregnant or planning on getting pregnant during the study
- Contain a minimum of 2 traits of metabolic syndrome
- Refused to participate in the surgery and refused informed consent
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04444349
Start Date
February 1 2021
End Date
December 31 2025
Last Update
November 27 2024
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China
2
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
3
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210029
4
West China Hospital of Sichuan University
Chengdu, Sichuan, China